EUCTR2005-001300-39-IT进行中（未招募）不适用
A phase 2, multi-centre, randomized, double-blind, placebo-controlled, parallel-group 3 arms pilot study to assess the efficacy, the safety and the pharmacokinetics of two treatment schedules of reparixin in the prevention of delayed graft function after kidney transplantation in high risk patients.
DOMPE s.p.a.0 个研究点目标入组 72 人开始时间: 2006年1月30日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A study to assess the efficacy and safety of oral ladarixin given 400 mg twice a day in patients with new-onset type 1 diabetesnew onset type 1 diabetesMedDRA version: 20.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: HLT Classification code 10012602 Term: Diabetes mellitus (incl subtypes) System Organ Class: 100000004860MedDRA version: 20.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 20.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003968-20-DEDompé farmaceutici s.p.a.72
进行中（未招募）
1 期
A study to assess the efficacy and safety of oral ladarixin given 400 mg twice a day in patients with new-onset type 1 diabetesnew onset type 1 diabetesMedDRA version: 18.0 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.0 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.0 Level: HLT Classification code 10012602 Term: Diabetes mellitus (incl subtypes) System Organ Class: 100000004860MedDRA version: 18.0 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.0 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003968-20-ITDompé farmaceutici s.p.a.72
进行中（未招募）
1 期
A study to assess the efficacy and safety of oral ladarixin given 400 mg twice a day in patients with new-onset type 1 diabetesnew onset type 1 diabetesMedDRA version: 18.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1 Level: LLT Classification code 10012608 Term: Diabetes mellitus insulin-dependent System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1 Level: HLT Classification code 10012602 Term: Diabetes mellitus (incl subtypes) System Organ Class: 100000004860MedDRA version: 18.1 Level: PT Classification code 10012601 Term: Diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersMedDRA version: 18.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2014-003968-20-BEDompé farmaceutici s.p.a.72
进行中（未招募）
1 期
A study to test the safety, tolerability, and the effects of C21 in patients with Idiopathic Pulmonary Fibrosis (IPF)Idiopathic Pulmonary Fibrosis (IPF)MedDRA version: 20.0 Level: PT Classification code 10021240 Term: Idiopathic pulmonary fibrosis System Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2017-004923-63-GBVicore Pharma AB30
招募中
2 期
A phase 2, multicenter, randomized, double-blind, placebo-controlled, dose-finding trial to evaluate the efficacy and safety of IMU-838 for treatment of patients with active Crohn*s disease with an option for open-label treatment extension (CALDOSE-2)10017969Crohn's DiseaseNL-OMON48184Immunic AG12